The dual-epitope nanobody anti-CD5 CAR-T therapy developed by Hebei Senlang Biotechnology represents a next-generation, first-in-human cellular immunotherapy designed to enhance antigen binding avidity and tumor cell targeting in R/R T-ALL/LBL and PTCL. Built on a nanobody-based CD5 targeting scaffold, this approach aims to improve CAR-T cell activation and overcome key resistance and persistence challenges observed with earlier CD5-directed strategies.

In the CONQUER trial, this novel CD5 CAR-T therapy demonstrated encouraging early clinical activity, with robust overall response rates and deep remission signals in heavily pretreated patients. Responses were particularly pronounced at higher dose levels, supported by minimal residual disease–negative remissions and improved expansion kinetics in responders, underscoring a clear exposure–response relationship. These early results support dual-epitope anti-CD5 CAR-T as a differentiated and promising cellular therapy candidate with potential to reshape outcomes in relapsed/refractory T-cell malignancies.

The results presented at ASCO 2026 were as follows:

Key Efficacy Highlights:

• Overall response rate (ORR): 77.8% 

• Complete response/complete remission with incomplete count recovery/complete molecular remission (CR/CRi/CMR): 61.1% 

• Partial response with extranodal disease: 16.7%  

• All responding patients with bone marrow involvement achieved minimal residual disease (MRD) negativity by flow cytometry 

• At recommended Phase II dose (RP2D; 2.0 ×10⁶ CAR-T cells/kg): ORR 100%, CR/CMR 85.7% 

• Five responding patients proceeded to consolidative allogeneic hematopoietic stem cell transplantation (allo-HSCT) 

• Non-response was associated with low CAR-T cell expansion (peak <500 copies/µg genomic DNA) 

Key Safety Highlights:

• No dose-limiting toxicities (DLTs); RP2D established at 2.0 ×10⁶ CAR-T cells/kg 

• Cytokine release syndrome (CRS) in 66.7%, all grade ≤2 (grade 2: 21.7%); no grade ≥3 CRS 

• Immune effector cell–associated neurotoxicity syndrome (ICANS) in 5.5% (grade 1 only) 

• Early immune-cell–associated hematotoxicity (ICAHT) observed across grades 1–4 (including grade 4 in 27.8%) 

• Epstein–Barr virus (EBV) reactivation in 50% and cytomegalovirus (CMV) viremia in 33.3%

KOL insights

“Nanobody-based CAR-T therapies offer distinct advantages over conventional CAR constructs, including enhanced tissue penetration and improved access to difficult-to-target epitopes, supporting their potential as a next-generation immunotherapy platform.” – Expert Opinion

“While nanobody-based CAR-T platforms are highly innovative, their clinical success will depend on overcoming key pharmacokinetic and manufacturing challenges, including short circulating half-life, rapid renal clearance, and production complexity. Advances in engineering strategies, such as Fc fusion and optimized nanobody design, are expected to improve durability and broaden their therapeutic applicability.”– Expert Opinion

Conclusion

T-ALL and PTCL are rare, aggressive malignancies with high relapse rates and limited durable treatment options. In 2025, PTCL accounted for 12,324 cases among T-cell malignancies in the United States, highlighting a continued gap in effective long-term disease control despite available chemotherapy, salvage regimens, and allogeneic hematopoietic stem cell transplantation, which remain largely non-curative in heavily pretreated patients. In this setting, dual-epitope nanobody anti-CD5 CAR-T therapy from the CONQUER trial emerges as a next-generation approach, demonstrating strong early efficacy with high response rates, deep complete remissions including minimal residual disease negativity, and robust CAR-T expansion, particularly at the recommended Phase II dose. The therapy also shows a manageable safety profile with no DLTs and mainly low-grade CRS and limited ICANS, collectively indicating a potential shift toward deeper and more durable disease control in relapsed/refractory T-cell malignancies.